Jean-Jacques Bienaimé, BioMarin CEO
BioMarin touts Voxzogo sales bump in Q2 results, notes 'temporarily tight supply'
BioMarin is touting “record revenues” from the first half of 2023, spearheaded by the jump in sales of its achondroplasia drug Voxzogo — so much so …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
